It has already shown to be efficacious in renal cell cancer (RCC) in a phase II randomized discontinuation trial in 225 patients with metastatic RCC.[44] At ASCO 2008, a randomized study compared pazopanib 400 mg daily plus lapatinib 1000 mg daily to lapatinib 1500 mg daily alone in patients with untreated HER2 positive advanced or MBC in the first-line setting.[45] The progressive disease rate was higher in the lapatinib alone group when compared to the combination group (27% vs 19%). This evidence concerns the gene ERBB2 and renal cell adenocarcinoma.